Coastal Georgia's U.S. House seat is open as Congressman Buddy Carter has launched a U.S. Senate bid. Yet, no high-profile elected officials or business leaders have entered.

The New England Patriots continue to make adjustments to their 90-man roster in the wake of rookie minicamp, which was held from May 9-11 at Gillette Stadium. The Patriots announced, on Monday ...

Despite being married and having a fulfilling career as a sophisticated arts foundation director, something is missing in Oh Hye Won's life. When she meets twenty-something Lee Seon Jae, Hye Won's ...

Pfizer will focus on Hympavzi, the first U.S.-approved anti-TFPI for hemophilia. Beqvez was FDA-approved in April 2024 but saw low adoption from patients. Discover how Matt Maley trades sharp ...

Late last week, Novo revealed that the FDA approved its tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes ...

HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the European Union (EU) for the treatment of hemophilia A or B and the first hemophilia medicine ...

Hye Won tells Sun Jae to not meet or call her for awhile after she receives a text from a man who knows about their secret meeting place. Joon Hyung tells Hye Won to end her relationship with Sun ...

But of greater concern for Centessa was the approval granted last month to Hympavzi, Pfizer’s anti-tissue factor pathway inhibitor, for patients aged 12 and older with hemophilia A or B who have ...

The following is a summary of “Effect of therapeutic plasma exchange on tissue factor and tissue factor pathway inhibitor in septic shock,” published in the October 2024 issue of Critical Care by ...

Hympavzi is a new type of drug that works by reducing the amount of the naturally occurring anticoagulation protein called tissue factor pathway inhibitor, thus increasing the amount of thrombin ...

On Friday, the FDA signed off on Hympavzi (marstacimab-hncq), an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B who have not developed antibodies to ...